Charles River raises profit forecast on growing demand for drug development services

Charles River Laboratories International

06/08/2025 12:54

Aug 6 (Reuters) - Charles River Laboratories CRL.N on Wednesday raised its annual profit forecast, betting on growing demand for its drug discovery and development services from drugmakers, sending its shares up more than 4% in premarket trading.

The Wilmington, Massachusetts-based contract drug developer raised its 2025 adjusted profit forecast to $9.90 to $10.30 per share, compared with its previous projection of $9.30 to $9.80.

Contract research organizations, which reported quarterly results over the last month, have all posted better-than-expected profit, reflecting a rebound in spending from pharmaceutical and biotech clients after a cautious stretch driven by tighter sector financing.

Companies such as Danaher DHR.N, Medpace 
Recent news on Charles River Laboratories International
See all news
Brief: Charles River, Labcorp, And FDA Collaborate To Validate New Preclinical Methods For Abuse Potential Assessment
Yesterday 23:19
S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT
Wed 20:30
S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT
Wed 17:00
S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT
Tue 17:00
European life sciences stocks rise on strong sector momentum
06/10/2026 09:58